Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of cisplatin + 5-fluorouracil + nimotuzumab for untreated metastatic nasopharyngeal carcinoma
ChiCTR-ONC-12002130Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Overall objective response rate and Progression-free survival. Started May 2012; status: completed.
02
Drugs
nimotuzumabcisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-ONC-12002130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002130.